{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Zimberelimab+%28AB122%29", "query": { "intervention": "Zimberelimab (AB122)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 32, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Zimberelimab+%28AB122%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-26T02:56:27.707Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07619313", "title": "AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Borderline Resectable Pancreatic Ductal Adenocarcinoma", "Locally Advanced Cholangiocarcinoma", "Locally Advanced Pancreatic Adenocarcinoma", "Metastatic Cholangiocarcinoma", "Metastatic Pancreatic Adenocarcinoma", "Stage II Pancreatic Cancer AJCC v8", "Stage III Pancreatic Cancer AJCC v8", "Stage IV Pancreatic Cancer AJCC v8" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Ligritinib", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Zimberelimab", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2026-05-29", "completion_date": "2028-06-01", "has_results": false, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-09-26T02:56:27.707Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07619313" }, { "nct_id": "NCT06048484", "title": "Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "Stereotactic body radiotherapy (SBRT)", "type": "RADIATION" }, { "name": "Zimberelimab", "type": "DRUG" }, { "name": "Quemliclustat", "type": "DRUG" }, { "name": "Etrumadenant", "type": "DRUG" }, { "name": "Modified FOLFIRINOX", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "Gulam Manji", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2024-05-10", "completion_date": "2027-04", "has_results": false, "last_update_posted_date": "2026-02-27", "last_synced_at": "2026-09-26T02:56:27.707Z", "location_count": 5, "location_summary": "Lake Success, New York • New York, New York • Chapel Hill, North Carolina + 2 more", "locations": [ { "city": "Lake Success", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT06048484" }, { "nct_id": "NCT05502237", "title": "Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Zimberelimab", "type": "DRUG" }, { "name": "Domvanalimab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1021, "start_date": "2022-10-12", "completion_date": "2029-01", "has_results": false, "last_update_posted_date": "2026-01-30", "last_synced_at": "2026-09-26T02:56:27.707Z", "location_count": 11, "location_summary": "Whittier, California • Washington D.C., District of Columbia • Tampa, Florida + 8 more", "locations": [ { "city": "Whittier", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Tampa", "state": "Florida" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Asheville", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05502237" }, { "nct_id": "NCT04772989", "title": "A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "Non Small Cell Lung Cancer (NSCLC)", "Melanoma", "Cervical Cancer", "Multiple Myeloma", "Lymphoma, Non-Hodgkin", "Diffuse Large B Cell Lymphoma (DLBCL)", "Gastric Cancer", "Gastroesophageal Junction Adenocarcinoma", "Esophageal Cancer" ], "interventions": [ { "name": "AB308", "type": "DRUG" }, { "name": "Zimberelimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arcus Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 94, "start_date": "2021-03-19", "completion_date": "2025-08-25", "has_results": false, "last_update_posted_date": "2025-08-28", "last_synced_at": "2026-09-26T02:56:27.707Z", "location_count": 15, "location_summary": "Los Angeles, California • Jacksonville, Florida • Goshen, Indiana + 12 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Goshen", "state": "Indiana" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT04772989" }, { "nct_id": "NCT05536141", "title": "A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Clear Cell Renal Cell Carcinoma", "Solid Tumors" ], "interventions": [ { "name": "casdatifan", "type": "DRUG" }, { "name": "Cabozantinib", "type": "DRUG" }, { "name": "Zimberelimab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arcus Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 362, "start_date": "2022-10-26", "completion_date": "2029-03", "has_results": false, "last_update_posted_date": "2026-08-31", "last_synced_at": "2026-09-26T02:56:27.707Z", "location_count": 20, "location_summary": "Birmingham, Alabama • San Diego, California • Santa Monica, California + 13 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Diego", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05536141" }, { "nct_id": "NCT04087018", "title": "Study to Evaluate Safety and Clinical Activity of AB122 in Biomarker Selected Participants With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "zimberelimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arcus Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2019-09-24", "completion_date": "2024-06-17", "has_results": false, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-09-26T02:56:27.707Z", "location_count": 9, "location_summary": "Riverside, California • Roseville, California • Newark, Delaware + 5 more", "locations": [ { "city": "Riverside", "state": "California" }, { "city": "Roseville", "state": "California" }, { "city": "Newark", "state": "Delaware" }, { "city": "Gaithersburg", "state": "Maryland" }, { "city": "Saint Louis Park", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04087018" }, { "nct_id": "NCT04791839", "title": "Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer", "Non-small Cell Carcinoma", "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Zimberelimab", "type": "DRUG" }, { "name": "Domvanalimab", "type": "DRUG" }, { "name": "Etrumadenant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2021-08-04", "completion_date": "2030-12-31", "has_results": false, "last_update_posted_date": "2026-06-08", "last_synced_at": "2026-09-26T02:56:27.707Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04791839" }, { "nct_id": "NCT05335941", "title": "A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Urothelial Carcinoma", "Metastatic Cancer" ], "interventions": [ { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Zimberelimab", "type": "DRUG" }, { "name": "Etrumadenant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2023-06-13", "completion_date": "2027-09-30", "has_results": false, "last_update_posted_date": "2026-08-14", "last_synced_at": "2026-09-26T02:56:27.707Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05335941" }, { "nct_id": "NCT07397611", "title": "Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Renal Cell Carcinoma", "Kidney Cancer", "Kidney Neoplasm", "Renal Carcinoma" ], "interventions": [ { "name": "Casdatifan", "type": "DRUG" }, { "name": "Zimberelimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2026-03-09", "completion_date": "2029-09-30", "has_results": false, "last_update_posted_date": "2026-03-20", "last_synced_at": "2026-09-26T02:56:27.707Z", "location_count": 3, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07397611" }, { "nct_id": "NCT03846310", "title": "A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non Small Cell Lung Cancer Metastatic", "Non Small Cell Lung Cancer", "Nonsquamous Nonsmall Cell Neoplasm of Lung", "Sensitizing EGFR Gene Mutation" ], "interventions": [ { "name": "Etrumadenant", "type": "DRUG" }, { "name": "Zimberelimab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arcus Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 77, "start_date": "2019-04-01", "completion_date": "2024-11-18", "has_results": false, "last_update_posted_date": "2024-12-09", "last_synced_at": "2026-09-26T02:56:27.707Z", "location_count": 8, "location_summary": "Tucson, Arizona • Fort Myers, Florida • Tavares, Florida + 5 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Tavares", "state": "Florida" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03846310" } ] }